Radiotherapy & Oncology
Volume 87, Issue 1 , Pages 55-58 , April 2008

Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: A feasibility study

  • Angela van Baardwijk

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW , University Hospital Maastricht, Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Angela van Baardwijk, Department of Radiation Oncology (MAASTRO), GROW, University Hospital Maastricht, Dr. Tanslaan 12, 6229 ET Maastricht, The Netherlands.
    • ,
  • Geert Bosmans

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW , University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Robert Jan van Suylen

      Affiliations

    • Department of Pathology , University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Marinus van Kroonenburgh

      Affiliations

    • Department of Nuclear Medicine , University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Monique Hochstenbag

      Affiliations

    • Department of Respiratory Medicine , University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Gijs Geskes

      Affiliations

    • Department of Cardiothoracic Surgery, University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW , University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW , University Hospital Maastricht, Maastricht, The Netherlands

Received 12 September 2007 ,Revised 21 January 2008 ,Accepted 3 February 2008.

References 

  1. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol. 2003;45:49–59
  2. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev. 2006;32:245–260
  3. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–225
  4. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  5. Mamede M, Higashi T, Kitaichi M, et al. [18F]-FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7:369–379
  6. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]-fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683–691
  7. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392–1398
  8. Dearling JL, Flynn AA, Sutcliffe-Goulden J, et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med. 2004;45:101–107
  9. Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005;46:675–682
  10. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317–322
  11. International Commission on Radiological Protection. Radiation dose to Patients from Radiopharmaceuticals, Publication 80. Oxford: Pergamon Press; 1999.
  12. Chan R, He Y, Haque A, Zwischenberger J. Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience. Arch Pathol Lab Med. 2001;125:1469–1472
  13. Grills IS, Fitch DL, Goldstein NS, et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys. 2007;
  14. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48:1015–1024
  15. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [(18)F]-fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683–691
  16. Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. Int J Radiat Oncol Biol Phys. 2005;62:854–861
  17. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545–553
  18. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122–1227

PII: S0167-8140(08)00088-1

doi: 10.1016/j.radonc.2008.02.002

Radiotherapy & Oncology
Volume 87, Issue 1 , Pages 55-58 , April 2008

Article Tools

* Image Usage & Resolution